193 related articles for article (PubMed ID: 23855906)
1. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout.
Gläsker S; Lulla A; Lulla V; Couderc T; Drexler JF; Liljeström P; Lecuit M; Drosten C; Merits A; Kümmerer BM
Virol J; 2013 Jul; 10():235. PubMed ID: 23855906
[TBL] [Abstract][Full Text] [Related]
2. High-Throughput Platform for Detection of Neutralizing Antibodies Using Flavivirus Reporter Replicon Particles.
Lücke AC; Vom Hemdt A; Wieseler J; Fischer C; Feldmann M; Rothenfusser S; Drexler JF; Kümmerer BM
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215941
[TBL] [Abstract][Full Text] [Related]
3. Development of a Novel Chikungunya Virus-Like Replicon Particle for Rapid Quantification and Screening of Neutralizing Antibodies and Antivirals.
Lin HC; Chiao DJ; Shu PY; Lin HT; Hsiung CC; Lin CC; Kuo SC
Microbiol Spectr; 2023 Mar; 11(2):e0485422. PubMed ID: 36856407
[TBL] [Abstract][Full Text] [Related]
4. A neutralization assay for chikungunya virus infections in a multiplex format.
Weber C; König R; Niedrig M; Emmerich P; Schnierle BS
J Virol Methods; 2014 Jun; 201():7-12. PubMed ID: 24552952
[TBL] [Abstract][Full Text] [Related]
5. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
Chua CL; Sam IC; Merits A; Chan YF
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
[TBL] [Abstract][Full Text] [Related]
6. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate.
Chung WC; Hwang KY; Kang SJ; Kim JO; Song MJ
J Microbiol; 2020 Jan; 58(1):46-53. PubMed ID: 31768937
[TBL] [Abstract][Full Text] [Related]
7. Development of Neutralization Assay Using an eGFP Chikungunya Virus.
Deng CL; Liu SQ; Zhou DG; Xu LL; Li XD; Zhang PT; Li PH; Ye HQ; Wei HP; Yuan ZM; Qin CF; Zhang B
Viruses; 2016 Jun; 8(7):. PubMed ID: 27367716
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Methods for CHIKV Based on Serological Tools.
Gaibani P; Landini MP; Sambri V
Methods Mol Biol; 2016; 1426():63-73. PubMed ID: 27233261
[TBL] [Abstract][Full Text] [Related]
9. Identification of the corticotropin-releasing factor receptor 1 antagonists as inhibitors of Chikungunya virus replication using a Gaussia luciferase-expressing subgenomic replicon.
Watanabe Y; Suzuki Y; Emi A; Murakawa T; Hishiki T; Kato F; Sakaguchi S; Wu H; Yano T; Lim CK; Takasaki T; Nakano T
Biochem Biophys Res Commun; 2022 Dec; 637():181-188. PubMed ID: 36403481
[TBL] [Abstract][Full Text] [Related]
10. Generation of a recombinant West Nile virus stably expressing the Gaussia luciferase for neutralization assay.
Zhang PT; Shan C; Li XD; Liu SQ; Deng CL; Ye HQ; Shang BD; Shi PY; Lv M; Shen BF; Qin CF; Zhang B
Virus Res; 2016 Jan; 211():17-24. PubMed ID: 26415755
[TBL] [Abstract][Full Text] [Related]
11. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
[TBL] [Abstract][Full Text] [Related]
12. Neutralization Assay for Chikungunya Virus Infection: Plaque Reduction Neutralization Test.
Azami NA; Moi ML; Takasaki T
Methods Mol Biol; 2016; 1426():273-82. PubMed ID: 27233280
[TBL] [Abstract][Full Text] [Related]
13. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
[TBL] [Abstract][Full Text] [Related]
14. Preparation and application of chikungunya pseudovirus containing double reporter genes.
Su C; Ding K; Xu J; Wu J; Liu J; Shen J; Zhou H; Liu H
Sci Rep; 2022 Jun; 12(1):9844. PubMed ID: 35701460
[TBL] [Abstract][Full Text] [Related]
15. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
16. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
[TBL] [Abstract][Full Text] [Related]
17. Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein.
Tong W; Yin XX; Lee BJ; Li YG
Acta Virol; 2015 Jun; 59(2):189-93. PubMed ID: 26104337
[TBL] [Abstract][Full Text] [Related]
18. Characterization of antibody response in patients with acute and chronic chikungunya virus disease.
Anfasa F; Lim SM; Fekken S; Wever R; Osterhaus ADME; Martina BEE
J Clin Virol; 2019 Aug; 117():68-72. PubMed ID: 31229935
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
20. Serological Responses in Patients Infected with Mayaro Virus and Evaluation of Cross-Protective Responses against Chikungunya Virus.
Bopp NE; Jencks KJ; Siles C; Guevara C; Vilcarromero S; Fernández D; Halsey ES; Ampuero JS; Aguilar PV
Am J Trop Med Hyg; 2021 Nov; 106(2):607-609. PubMed ID: 34844213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
